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Abstract 
Background: Participation in a clinical trial is believed to benefit patients but little is 
known about the post-trial effects on routine hospital-based care. 
Objectives: To describe 1) hospital-based, pressure ulcer care-processes after 
patients were discharged from a pressure ulcer prevention, cluster randomised 
controlled trial; and 2) to investigate if the trial intervention had any impact on 
subsequent hospital-based care. 
Methods: We conducted a retrospective analysis of 133 trial participants who 
developed a pressure ulcer during the clinical trial. We compared outcomes and care 
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processes between participants who received the pressure ulcer prevention 
intervention and those in the usual care, control group. We also compared care 
processes according to the pressure ulcer stage.  
Results: A repositioning schedule was reported for 19 (14.3%) patients; 33 (24.8%) 
had a dressing applied to the pressure ulcer; 17 (12.8) patients were assessed by a 
wound care team; and 20 (15.0%) were seen by an occupational therapist. Patients 
in the trial’s intervention group were more likely to have the presence of a pressure 
ulcer documented in their chart (odds ratio (OR) 8.18, 95% confidence intervals (CI) 
3.64 to 18.36); to be referred to an occupational therapist OR 0.92 (95% CI 0.07; 
0.54); to receive a pressure relieving device OR 0.31 (95% CI 0.14; 0.69); or a 
pressure relieving mattress OR 0.44 (95% CI 0.20; 0.96). Participants with Stage 2 or 
unstageable ulcers were more likely than others to have dressings applied to their 
wounds (p = < 0.001) and to be referred to an occupational therapist for protective 
devices (p = 0.022). 
Conclusion:  
Participants in the intervention group of a clinical trial were more likely to receive 
additional post trial care and improved documentation compared with those in the 
control group but documentation of pressure ulcer status and care is poor. 
 
Keywords:Follow-Up Studies; Pressure Ulcer; Nursing; Outcome and Process 
Assessment (Health Care). 
 
 
What is already known about the topic: 
 Pressure ulcers continue to occur among patients with limited mobility 
 Few interventions have shown to be effective in preventing pressure ulcers in 
this cohort 
 There is a dearth of information about the impact of participating in a 
randomised controlled trial on subsequent pressure ulcer management. 
What this paper adds: 
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 Participation in the intervention arm of a clinical trial increases care provided 
after the trial ends 
 Participation in the intervention arm of a clinical trial improves 
documentation of care in clinical notes 
 Processes of pressure ulcer care is very poorly reported in clinical notes. 
 
 
BACKGROUND 
Despite expensive prevention programs (1) and payment-removal penalties (2), 
pressure ulcers (PUs) continue to occur among patients admitted to acute care 
facilities. Incidence and prevalence rates of hospital acquired pressure ulcers vary 
depending on the practice setting between 0.0 to 72.5% (3), with highest rates 
among critical care, spinal cord injury and other patients with limited mobility (4, 5). 
The cost of PU prevention is substantial, ranging from €2.65 to €87.57 per patient 
per day. Costs associated with PU treatment are even higher with estimates from 
€1.71 to € 470.49 (6). In Australia, a recent cost-of-illness study estimated 121,645 
cases of PUs per year contributed to 524,661 bed days lost for an estimated cost of 
AUD $983 million per year (based on 2012/2013)(7). More importantly, pressure 
ulcer-related pain is often severe and its presence increases the likelihood of 
developing a higher stage ulcer (8).  
 
Although potentially preventable, there is a paucity of high level PU research to 
guide practice. For example, in the recent authoritative clinical guideline document 
we found only six of the 558 recommendations for pressure ulcer prevention and 
treatment were supported by Level A evidence (3); that is, a recommendation 
supported by “direct scientific evidence from properly designed and implemented 
controlled trials on pressure ulcers in humans” (p.3). Moreover, of the six 
recommendations with Level A evidence, only one, the recommendation relating to 
the use of high specification reactive foam mattresses, was supported by studies 
showing that the intervention was beneficial (9). For the other five 
recommendations, although high quality studies existed, the body of evidence from 
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those studies indicated that the effectiveness of the intervention remained unclear; 
for example evidence around diet (10) and repositioning (11). 
 
Major risk factors for PUs are well known and include 1) immobility; 2) physiological 
conditions that limit blood flow to vulnerable tissue, such as diabetes and vascular 
disease; and 3) skin condition or existing pressure ulcer status (12). Similarly, costs of 
treating PUs (6) and incidence/prevalence  are well reported (12). There are also 
numerous studies describing outcomes from PU prevention programs (1, 13) but few 
of these provide information about processes of care; such as the use of preventive 
dressings, mattress type, frequency of referrals to wound-care experts or other 
specialist. Of the 24 studies included in a review of PU programs, only seven 
reported the rate of adherence to planned care processes and none describe 
strategies for treating new PUs (13).  
 
We were able to find only one study, in an acute hospital setting, describing the day-
to-day management subsequent to the identification of a PU (14). In this study, 
conducted in one community hospital in the USA, the medical records of 100 
patients with a PU on admission or who developed a PU during their hospital stay 
were reviewed. Information was provided about bed/mattress type, use of topical 
applications, frequency of turning and referrals to surgical services; but other 
interventions, like use of dressings and other pressure relieving devices and referrals 
to other specialists, such as podiatrists or occupational therapists were not reported 
(14). One further study included a medical record review of patients who had 
developed a PU during their acute hospital stay but the only process indicator was 
referral to a specialist skin integrity nurse (15). 
 
As there is a dearth of information in this area, the extent to which guidelines for PU 
treatment (3) are followed is unclear. We recently completed a multi-site, cluster 
randomised trial that evaluated a patient-centred, PU prevention care bundle 
intervention (16). Details of the intervention are reported elsewhere (16) but, briefly, 
the intervention consisted of a short DVD and an information leaflet and poster. The 
poster and information leaflet contained three main messages1) keep moving; 2) 
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look after your skin; and 3) eat a healthy diet. These messaged were reinforced orally, 
while the intervention was being delivered to the patient. Nursing staff also received 
education sessions about the intervention and were asked to support the messages 
during their patient contact. The study end-point was the development of a new PU. 
However, when the end point was reached, no further information was collected. 
Subsequently, we sought permission to conduct a follow-up study, to explore the 
care participating patients in both arms of the study received following the 
development of a PU.  
 
The aim of the present study was two-fold: 1) to describe the care processes 
implemented by hospital staff following identification of a PU and 2) to investigate if 
the intervention had any impact on subsequent care. 
 
MATERIALS AND METHODS 
Patients 
In this follow-up study, we retrospectively evaluated the follow-up care of the 133 
adult patients who developed a PU, of any stage during a recent cluster randomised 
controlled trial (16). The trial was conducted at eight hospitals in three Australian 
states between June 2014 and May 2015. Inclusion criteria for the trial involved 
having reduced mobility, expected hospital stay of >24h; admitted to hospital within 
the past 36h; and able to provide informed consent. The follow-up study of patients 
from both arms of the trial was approved by the Ethics Committees of the 
administering university and the participating hospitals. 
Patient record review 
Using a purposefully designed data extraction tool, developed by the investigators, 
trained registered nurses and one dietitian retrospectively reviewed the nursing, 
medical and allied health entries in each patient’s medical record. Where available, 
other materials, such as daily care plans and wound care pathways were also 
reviewed. We extracted information about the stage of the PU identified in the 
original trial (target PU); interventions to treat the target PU; interventions 
implemented and/or recommended by hospital staff to prevent further PU 
development (such as a turning regime); incidence of any new PU and any treatment 
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(for example dressings or topical agents) associated with any new PU. We also 
extracted data about any post-discharge referrals associated with follow-up care for 
PUs or PU related re-admissions. After the medical record review was completed we 
added demographic and risk factor data, such as comorbid conditions (diabetes, 
vascular disease) and body mass index (BMI) from the INTACT trial database. We also 
included the stage of the target PU at the trial endpoint. 
Statistical analysis 
Descriptive statistics are reported as frequencies (%) or mean and standard deviation 
(SD). To test for any differences between the subsequent PU management of original 
trial groups; and for any differences between the subsequent PU management by PU 
stages, all categorical data were analysed using the Chi-squared test or two-tailed 
Fisher’s exact test if one of the cells had a very small expected count. Continuous 
variables were not normally distributed so we used the Mann-Whitney U Test to 
assess for differences in continuous variables. Between group comparisons are 
presented as odds ratios (OR) or mean difference (MD). Data were analysed using 
IBM SPSS Statistics 23 and significance was defined as p = 0.05. Sample 
characteristics, preventive interventions, treatments and post-discharge referrals are 
reported in two ways: 1) by the group to which participants were assigned in the 
original cluster RCT; and 2) by the pressure ulcer stage on discharge from the trial.  
 
Results 
Of the 133 participants included in the follow-up study, 67 (50.4%) were female. The 
mean age of participants was 75.7 years (SD 14.3); mean BMI was 28.23kg/m2 (SD 
8.94; range 13.1 to 69.4) and average length of stay was 12.6 days (SD 11.97). A total 
of 128 (94%) were assessed for PU risk on admission and, of the 103 patients who 
were assessed with the Waterlow scale, 99 (96.1%) scored > 9 (i.e. were at risk of 
PU). The majority, 73 (54.9%) were receiving internal medicine care, 58 (43.6%) were 
surgical patients and two (1.5%) were receiving cancer care. Less than half, 63 
(47.4%) were living independently; the majority, 90 (67.7%) reported more than one 
co-morbidity and 37 (27.8%) had a PU on admission to hospital.  
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A repositioning schedule was reported for 19 (14.3%) patients and 33 (24.8%) had a 
dressing applied to the PU. In terms of referrals, 17 (12.8%) patients were assessed 
by a wound care team, two (1.5%) saw a dietitian; 20 (15.0%) were seen by an 
occupational therapist and two (1.5%) had an orthotics referral. At hospital discharge 
the outcome for 99 (74.4%) PU was not recorded; 17 (12.8%) were recorded as 
healed; 11 (8.3%) were Stage 1; five (3.8%) were Stage 2; and one (0.8%) was Stage 
3. Documentation at discharge was more likely if the patient had a Stage 2 PU (p = 
0.006). There was no record of any referral to a care provider for PU management 
following hospital discharge and no indication that any participant returned to an 
outpatient clinic for PU care. 
 
Overall, 60 (45.1%) PUs identified during the INTACT trial were documented in the 
patient’s medical record. Documentation varied, depending on the group to which 
the patient had been assigned during the trial. A PU was 8-times more likely to be 
reported in the medical record of those who had been assigned to the INTACT trial’s 
intervention group (p = < 0.001) compared with the trial’s control group. Those in 
the intervention group were also more likely than those in the control group to have 
the stage of the PU recorded when the patient was discharged from hospital (p = 
0.007); a record that a dressing had been applied to the target PU (p < 0.04); been 
referred to a wound care team (p < 0.001) or an occupational therapist (p = 0.001); 
and a prophylactic pressure relieving device (p = 0.005) or mattress (p = 0.03) as part 
of their care (Table 1). 
 
The stage of a PU also influenced whether the lesion would be reported in the 
medical record, with Stage 2 being the most frequently recorded (p < 0.02). 
Participants with Stage 2 or unstageable ulcers were more likely than others to have 
dressings applied to their wounds (p < 0.001) and to be referred to an occupational 
therapist for protective devices (p = 0.022). PU stage had no influence for any other 
interventions. Fifteen (11.3%) patients developed an additional PU during their 
subsequent hospital stay (Table 2).  
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Discussion 
Under trial conditions, interventions are carefully administered, monitored and 
reported but less is known about the effect of the intervention once a patient has 
been discharged from the trial. Our study is the first, prospectively designed 
investigation into the management of PUs in an acute care setting following 
participation in a randomised controlled trial. We undertook a medical record 
review, using a purposefully designed data extraction tool, to follow-up 133 patients 
who developed a PU during our recently completed clinical trial. We recorded 
subsequent treatment for any PU that developed during the trial and any 
intervention aimed at preventing development of a new PU. Whilst not pre-specified 
in the original INTACT trial, this post-hoc analysis has been undertaken to identify PU 
prevention and management strategies following a PU prevention intervention, in 
order to generate hypotheses for future trials.  
 
Although unexpected, we have shown considerable post-trial differences in both the 
documentation of PU care and the management of PUs between the INTACT trial 
intervention and control groups. Whether these differences (such as higher rate of 
dressing use or referral to an occupational therapist) were due to a real effect of the 
intervention or to differences in the capacity of hospitals in the control group to 
provide these interventions is unclear. The trial was a cluster randomised trial with 
hospitals randomised according to their baseline PU rate; so it was possible that 
differences existed in access to resources in some hospitals (for example all public 
hospitals employ occupational therapists whereas some private hospitals may not). 
However, private and public hospitals were evenly distributed in the control and 
intervention groups. Consequently, we hypothesise that differences were due to the 
intervention, which was aimed at raising patient, carer and nurse awareness about 
PU prevention and patients participating in this. There is some evidence to support a 
favourable effect on outcomes through participation in clinical trials (17, 18) but at 
least one study has shown that, although processes of care may improve; outcomes 
between intervention and controls remained similar (19). Our study was too small to 
test if the improved processes of care in the intervention group affected the 
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outcome (incidence of new PUs) but the data we do have, suggests that further 
investigation into this proposition is warranted. 
 
Irrespective of the higher use of PU prevention and treatment strategies in the 
INTACT intervention group participants, overall use of these strategies was low. This 
was despite clinical staff being notified when a PU was identified during the trial, 
providing an opportunity for staff to document and review their patients’ PU 
treatment. One of the most predictive indicators for developing a PU is the presence 
of an existing PU (15). Consequently, all of the patients in our follow-up study were 
at high risk for developing a second PU, yet only 14.3% had a repositioning schedule 
documented, an intervention generally accepted as the most basic and fundamental 
PU prevention strategy (3). Similarly, only around one third of patients with an 
existing PU received a pressure relieving device or mattress as part of their care.  
 
The study demonstrates that documentation of care following the development of a 
PU is poor. For example, although all of the patients in the study had an existing PU, 
any information about the PU was found in less than half of the patient’s clinical 
notes. This result is almost identical to outcomes from a Swedish prevalence survey 
where only 47% of skin assessments were documented in the electronic medical 
record (20), and similar to findings from  American acute care centres, where just 
46% of PUs that were found on clinical examination were documented in the 
electronic medical record (21). Even more disappointing, by the time study 
participants were discharged from hospital, the outcome (healed or otherwise) was 
recorded for only 14% of all PUs.  Whether poor documentation was due to low 
levels of skin inspection, or simply a failure to document the findings of skin 
inspections, is unclear. Never-the-less, poor reporting has a number of implications. 
Documentation is a means of conveying information from one health care provider 
to another, so care may be compromised if documentation is incomplete; especially 
if documentation is used to prompt PU prevention interventions.  Additionally, when 
under-reporting is present, chart audits may reveal incorrect results and lead to a 
false sense of security around PU rates, preventing quality improvement activities 
from occurring. Similarly, only patients who had limited mobility and therefore 
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deemed as high risk of developing a PU were admitted to the INTACT trial. Arguably, 
failure to document any follow-up care on these high-risk individuals represents an 
important omission and may be damaging in the event of any future legal action 
against the organisation. It is reasonable to assume that ‘‘what was not documented 
was not done.’’(22) p100. 
 
Limitations 
The study was post-hoc, designed after completion of the main study. Consequently, 
it was not powered to find differences between groups. Confidence intervals were 
wide, indicating a great deal of uncertainty around the effect size. Even so, the study 
has raised some interesting questions for future research in this area (for example, 
‘does improving processes of care result in improved outcomes?’). Secondly, the 
results relied on medical record reporting. We had no way of validating that all of the 
care provided was recorded in the patient’s record; some care may have been 
provided but not recorded. Our data extraction tool was based on the outcomes we 
wished to measure; the reliability of the tool was not assessed, for example by using 
a second person to validate the extracted data. In addition, data extractors were not 
directly informed of the allocation status of the hospital (intervention or control) but 
it is possible that they may have become aware of this status; thus compromising 
outcome blinding. Finally, results may not be generalized due to the small sample 
size, although participants were from a range of hospitals, which represented 
different levels of care. 
 
Conclusion 
Medical record evidence indicates that participants in the intervention arm of a 
randomised controlled trial received more ‘post-trial’ PU prevention-care compared 
with patients in the control arm. Irrespective of the PU stage, interventions among 
those with an existing PU were low. PU care of an existing or newly acquired PU is 
inadequately documented. 
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Table 1. Demographic and risk factor data for patients who were included in the 
follow-up study. Results are reported by group allocation in the INTACT trial 
Sample baseline characteristics Intervention 
(N=49) 
n (%) 
Control 
(N=84) 
n (%) 
Female 25 (51.0) 44 (52.4) 
Aged care residence  7 (14.3) 13 (14.8) 
Admission type  
     Surgical                                              
     Medical 
     Cancer 
             
          
 25 (51.0)  
23 (46.9) 
1 (2.0) 
 
 
 
50 (39.3) 
50 (59.9) 
1 (1.2) 
Number of co-morbidities 
     Less than two 
     Two or three 
     Four or more 
 
17 (34.7) 
28 (57.1) 
6 (12.2) 
 
26 (30.9) 
44 (52.4) 
14 (16.7) 
Current Smoker 5 (10.2) 4 (4.8) 
 Mean (SDa) Mean (SD) 
Age in years 70.67 (15.01) 78.89 (13.11) 
Body Mass Index 29.41 (10.43) 27.54 (8.01) 
Length of stay 12.58 (10.83) 12.89 (15.85) 
 a Standard deviation
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Table 2: Outcomes and interventions, documented in the medical record following 
discharge from the INTACT trial, for all patients who developed a pressure ulcer 
during the trial (n = 133). Results reported by group allocation in the INTACT trial 
 
Post study outcome Intervention 
(N=49) 
n (%) 
Control  
(N=84) 
n (%) 
ORa [95% 
CIb] 
P-
valuec 
PUd reported in medical record at end of 
INTACT Trial  
37 (75.5) 23 (27.4) 8.18 (3.64; 
18.36) 
< 0.001 
PU stage reported at hospital discharge 19 (38.8) 15 (17.9) 2.91 (1.31; 
6.49) 
0.007 
Turning regime for PU reported in the 
INTACT Trial 
10 (20.4) 9 (10.7) 0.47 (0.18; 
1.25) 
0.101 
Dressing for PU reported in the INTACT Trial 17 (34.7) 16 (19.0) 0.44 (0.20; 
0.99) 
0.036 
Referral to wound team for PU reported in the 
INTACT Trial 
16 (32.7) 1 (1.2) 0.03 (0.00; 
0.16) 
< 0.001 
Referral to dietician for PU reported in the 
INTACT Trial 
1 (2.0) 1 (1.2) 0.58 (0.04; 
9.46) 
0.603 
Referral to occupationl therapist for PU 
reported in the INTACT Trial 
14 (28.6) 6 (7.1) 0.19 (0.07; 
0.54) 
0.001 
Prophylactic orthotics  2 (4.1) 1 (1.2) 0.28 (0.25; 
3.20) 
0.306 
Prophylactic turning regime  19 (38.8) 19 (22.6) 0.46 (0.21; 
0.99) 
0.072 
Prophylactic pressure relieving device  21 (42.9) 16 (10.0) 0.31 (0.14; 
0.69) 
0.005 
Prophylactic pressure relieving mattress 18 (36.7) 17 (20.2) 0.44 (0.20; 
0.96) 
0.031 
New PU after discharge from main study 8 (16.3) 7 (8.3) 0.47 (0.16; 
1.38)  
0.169 
Dressing to treat new PU 6/8 (75.0) 4/7 (57.1) 0.44 (0.53; 
4.26) 
0.608 
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Turning regime for new PU 5/8 (62.5) 5/7 (71.4)  1.5 (0.17; 
13.22) 
1.000 
Any other intervention to treat new PU 2/8 (25.0) 5/7 (71.4) 7.5 (0.76; 
74.16 
0.132 
 
a Odds Ratio; b Confidence interval; c Chi Square or Fisher’s Exact (2-sided); dPressure Ulcer 
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Table 3: Outcomes and interventions, documented in the medical record following 
discharge from the INTACT trial, for all patients who developed a pressure ulcer 
during the trial (n = 133).  Results reported by pressure ulcer stage during the INTACT 
trial. 
 
Post study outcome Stage 1 
N = 88 
Stage 2 
N = 35 
Unstageable or 
suspected deep 
tissue injury 
N = 10 
P-valuea 
PUb reported in medical record at end of 
INTACT Trial  
33 (37.5) 22 (62.9) 5 (50.0) 0.018 
PU stage reported at hospital discharge 16 (18.2) 16 (45.7) 2 (20.0) 0.006 
Turning regime for PU reported in the 
INTACT Trial 
9 (10.2) 8 (22.9) 2 (20.0) 0.169 
Dressing for PU reported in the INTACT 
Trial 
13 (14.8) 17 (48.6) 3 (30.0) < 0.001 
Wound team referral for PU reported in the 
INTACT Trial 
8 (9.1) 6 (17.1) 3 (30.0) 0.115 
Referral to dietician for PU reported in the 
INTACT Trial 
1 (1.1) 1 (2.9) 0 (0.0) 0.717 
Referral to occupationl therapist for PU 
reported in the INTACT Trial 
8 (9.1) 10 (28.6) 2 (20.0) 0.022 
Prophylactic orthotics  3 (3.4) 0 (0.0) 0 (0.0) 0.456 
Prophylactic pressure relieving device  25 (28.4) 11 (31.4) 1 (10) 0.402 
Prophylactic pressure relieving mattress 18 (20.5) 13 (37.1) 4 (40.0) 0.098 
Prophylactic turning regime  23 (26.1) 12 (34.3) 3 (30.0) 0.662 
New PU after discharge from the INTACT 
Trial 
9 (10.2) 4 (11.4) 2 (20.0) 0.651 
Dressing to treat new PU 6/9 (66.7) 2/4 (50.0) 2/2 (100.0) 0.472 
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Turning regime for new PU 7/9 (77.7)  1/4 (25.0) 2/2 (100.0) 0.099 
Any other intervention to treat new PU 3/9 (33.3) 3/4 (75.0) 1/2 (50.0) 0.739 
 Mean 
(SDc) 
Mean (SD) Mean (SD) P-valued 
Age in years 78.40 
(12.11) 
73.60 
(16.43) 
61.5 (16.36) 0.001 
BMI 27.40 
(7.51) 
27.60 
(7.79) 
37.73 (17.08) 0.002 
Length of stay 12.58 
(10.83) 
12.89 
(15.85) 
11.70 (3.92) 0.963 
 
 
a Chi Square or Fisher’s Exact (2-sided); bPressure Ulcer; c Standard deviation; d Mann-Whitney U test 
 
 
